Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

(2012) I Witzel et al.   BRITISH JOURNAL OF CANCER

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes

(2011) Rinat Yerushalmi et al.   BREAST CANCER RESEARCH AND TREATMENT

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy

(2011) Allan Lipton et al.   CANCER

C-MYCAlterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

(2010) Isabell Witzel et al.   BREAST CANCER RESEARCH AND TREATMENT

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer

(2009) Siân Lennon et al.   JOURNAL OF CLINICAL ONCOLOGY

Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy inHER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013

(2009) Lyndsay N. Harris et al.   JOURNAL OF CLINICAL ONCOLOGY

Topoisomerase IIα Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out

(2009) Francisco J. Esteva et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

(2008) V. Ludovini et al.   ANNALS OF ONCOLOGY

Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer

(2008) Vivien H. C. Bramwell et al.   BREAST CANCER RESEARCH AND TREATMENT

HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy

(2008) Kathleen I. Pritchard et al.   JOURNAL OF CLINICAL ONCOLOGY